HXTC 901 is a first-in-class platelet substitute, administered via intravenous infusion, designed to prevent more severe bleeding in surgery and trauma.

The product is a ‘pro-drug’ of HaemoPlax and is activated by the action of thrombin, an enzyme present at wound sites. HXTC 901 is in exploratory trials. More...